

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Serial No.:	09/ 762,587	Group Art Unit:	1642
Confirmation No.:	5272	Examiner:	M.T. Davis
Filed (§ 371):	06 September 2001		
Applicant:	Antonio J. GRILLO-LÓPEZ		
For:	Use of Radiolabeled Anti-CD20 Antibody to Treat Rituximab-Refractory B-Cell Lymphoma (as amended)		

Mail Stop **AF**
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

NOTICE OF APPEAL UNDER 37 C.F.R. § 41.31(a)

Sir:

Applicant hereby appeals to the Board of Appeals and Interferences from the decision of the Primary Examiner mailed 7 December 2007 finally rejecting claim 7.

Applicant petitions under § 1.136(a) to extend the period for response to the final rejection by two months, to and including 7 May 2008. In view of the extension, the present notice of appeal is timely.

Applicant requests that the Director charge the extension fee of **\$460** (§ 1.17(a)(2)) and the appeal fee of **\$510** (§ 41.20(b)(1)), as well as any other fees required to render this notice timely or proper, to our **Deposit Account no. 18-1260**.

Respectfully submitted,

/David L. Fitzgerald/

David L. Fitzgerald, Reg. No. 47,347
Attorney for Biogen Idec Inc.

7 May 2008

SIDLEY AUSTIN LLP
1501 K Street, N.W.
Washington, DC 20005

tel. (202) 736-8818
fax (202) 736-8711